Hemab Therapeutics Holdings, In (COAG) Stock Price & How to Invest

Hemab Therapeutics Holdings (NASDAQ: COAG) is a clinical-stage biotechnology company founded in 2020 with operations in Cambridge, Massachusetts and Denmark. It develops therapies for rare and underserved bleeding disorders. Its lead candidate, sutacimig (HMB-001), is a bispecific antibody in development as a prophylactic treatment for Glanzmann thrombasthenia (which has a Breakthrough Therapy Designation) and Factor VII deficiency, with additional programs targeting von Willebrand disease (HMB-002) and heavy menstrual bleeding (HMB-003). The company has roughly 59 employees and no approved products or meaningful product revenue.

The investment picture is a classic clinical-stage biotech profile: no commercial sales, ongoing net losses (about $71 million over the trailing period), and a valuation (~$2.3 billion market cap in July 2026) built on the expected future value of its pipeline rather than current fundamentals. Hemab completed a NASDAQ IPO in May 2026 at $18 per share, raising roughly $347 million in gross proceeds, and the stock has since climbed toward $49. Management says its cash position funds operations into 2029, so financing pressure is low in the near term, but returns from here depend heavily on binary trial and regulatory outcomes over the next few years.

As a pre-revenue clinical-stage biotech, COAG carries substantial risk and its value depends on trial outcomes that are inherently binary. A failed or delayed Phase 3 readout for sutacimig could sharply reduce the stock, since no approved products or sales cushion the downside. The company continues to post net losses and will need commercial success (or further capital raises) to sustain itself beyond its stated runway into 2029. The stock has already run well above its $18 IPO price, so much optimism is embedded, and small, recently listed biotechs can be volatile and thinly followed. Regulatory setbacks, competitive therapies, or safety findings could each materially impair the thesis.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Hemab Therapeutics Holdings, In's investor relations page or your broker.

• Market cap: ~$2.3B
• Share price: ~$49
• Product revenue (TTM): ~$0 (pre-commercial)
• Net loss (trailing): ~-$71M
• Cash (post-IPO, into 2029): ~$480M
• IPO (May 2026): ~$18/share, ~$347M gross

COAG has no meaningful product revenue and is valued on the expected future worth of its pipeline, not on earnings, so standard metrics like P/E do not apply. Its roughly $2.3 billion market cap sits against ongoing net losses of about $71 million, offset by a strong cash position funding operations into 2029. The stock has risen from an $18 IPO price toward $49, meaning the market already prices in meaningful clinical success.

There are three common ways to get COAG exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so COAG sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where COAG fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

COAG is a well-funded but pre-revenue clinical-stage biotech whose value rests almost entirely on the outcome of its bleeding-disorder trials.

Whether COAG is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is COAG a buy?, and where the stock could go from here in the COAG stock forecast.

For income investors, whether COAG pays a dividend and how the payout looks is covered in does COAG pay a dividend?